Recruiting

MMA Embolization

Sponsor:

Lahey Clinic

Code:

NCT07715656

Conditions

Chronic Subdural Hematoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

embolization therapy Bilateral

embolization therapy Unilateral

Study Details

Brief summary:

This is a pragmatic, prospective, multicenter, randomized controlled trial with intention to treat analysis. In which subjects will receive either unilateral or bilateral middle meningeal artery (MMA) embolization using coils for the treatment of unilateral chronic subdural hematomas (cSDH).

Conditions

Chronic Subdural Hematoma

Study ID

NCT07715656

Start date

Apr 9, 2025

Status verified date

Mar, 2026

Completion date

Jun 30, 2027

Anticipated

Primary completion date

Apr 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Candidates for this study must meet ALL of the following criteria:

1. Subject is 18 years of age or older.
2. Subject has a diagnosis of chronic subdural hematoma with mass effect Determined by brain imaging (CT or MRI) and correlated clinical symptoms.
3. Pre-randomization modified Rankin Score (mRS) ≤3

a. Surgical Cohort: Assessment should reflect the subject's condition just prior to undergoing surgery. Assessment may be performed post-surgery using pre-surgical data.
4. Subdural Hematoma Size

Medical Management Cohort:
  • Midline shift < 10mm and hematoma thickness > 10 mm as measured on coronal imaging perpendicular to the skull.
  • No focal deficit related to the chronic subdural hematoma requiring surgical intervention

Surgical Cohort:

• No requirement
5. A CT performed prior to randomization demonstrating stability of the hematoma. Stability is defined as no worsening of midline shift or increase in the size of the cSDH from the screening image that results in new or worsening clinical symptoms.
6. Patient or designated Legal Authorized Representative, confirms the patient has the mental capacity, willingness and ability to comply with protocol and follow-up requirements
7. In the opinion of the treating physician, MMA embolization is technically feasible, including evaluation of preoperative CTA, if available, or presence of a foramen spinosum bilaterally.

Exclusion Criteria:

  • Candidates will be excluded from participation if ANY of the following apply:

1. Patients presenting with an acute SDH (e.g. patient with presenting with a SDH due to trauma); mixed density is permitted.
2. Subject presents with bilateral cSDHs requiring treatment (contralateral cSDH <5mm and not requiring treatment is permitted.
3. Subject presents with Glasgow Coma Scale < 9
4. Markwalder assessment >4
5. cSDH that developed with underlying conditions such as vascular lesions, brain tumor, arachnoid cyst, spontaneous intracranial hypotension, end stage renal disease (ESRD) on hemodialysis, end stage liver disease or other comorbidities causing a coagulopathy
6. Prior carotid stent placement that crosses the origin of the External Carotid Artery (ECA) ipsilateral to the subdural hematoma
7. Presumed septic embolus, or suspicion of microbial superinfection
8. CT or MRI evidence of intra-cranial tumor or mass lesion
9. Significant contraindication to angiography (eg. kidney failure).
10. Life expectancy of less than 1-year
11. Women who are pregnant, lactating, plan on becoming pregnant during the course of the clinical investigation. We routinely do pregnancy tests prior to this procedure, to avoid radiation exposure to the fetus including radiation on follow up CT scans
12. Current involvement in an investigational (drug, device, etc.) clinical trial that may confound study endpoints. Subjects in observational, natural history, and/or epidemiological studies not involving intervention are eligible
13. Patient unwilling to follow SOC recommendations (e.g. refuses surgery or lifestyle modifications)

Study Design

Enrollment

400 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Medical Management

In this cohort, subjects will undergo either unilateral or bilateral middle meningeal artery (MMA) embolization using coils as part of their medical management for chronic subdural hematoma (cSDH). In the unilateral arm, the MMA on the side of the hematoma is embolized, while in the bilateral arm, both sides are embolized regardless of hematoma location.

active comparator: Surgical

In this cohort, subjects will undergo either unilateral or bilateral middle meningeal artery (MMA) embolization using coils in addition to standard surgical management for chronic subdural hematoma (cSDH). In the unilateral arm, the MMA on the side of the hematoma is embolized, while in the bilateral arm, both sides are embolized regardless of hematoma location.

Interventions

embolization therapy Bilateral

In the bilateral approach, both middle meningeal arteries are accessed and embolized using coils, regardless of hematoma location. Imaging guidance is used throughout the procedure to ensure proper coil placement, and post-procedure imaging confirms that both vessels are fully occluded.

embolization therapy Unilateral

In the unilateral approach, the middle meningeal artery (MMA) on the side of the hematoma is accessed via a catheter and occluded using coils under imaging guidance. The procedure targets only the affected side, and follow-up imaging is used to confirm successful embolization and vessel occlusion.

Primary outcome measure

  • Change in cSDH Maximum thickness From Baseline on Non-contrast Head CT [ Time Frame: Baseline, 1 month (3-6 weeks), and 3 months (10-14 weeks) ]

Central Contacts and Locations

Central contacts

Locations

Lahey Hospital & Medical Center

Recruiting

Burlington, Massachusetts, United States, 01803

Contacts

More Information

Sponsor

Lahey Clinic

Last update posted

Jul 20, 2026

Last verified

Mar, 2026

Keywords

  • cSDH
  • Chronic subdural hematoma
  • Coils
  • Embolization
  • eMMA

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Lahey Clinic on 2026-07-20.